Neurogene Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Rachel L. McMinn
- Full Time Employees
- 131
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 535 W 24th Street New York City NY United States of America 10011
- IPO Date
- Mar 7, 2014
- CIK
- 0001404644
- Website
- neurogene.com
- Similar Companies
- Business
- Neurogene Inc. (Nasdaq: NGNE) is a clinical-stage biotechnology company that develops genetic medicines, including gene therapies utilizing adeno-associated virus vectors and proprietary transgene regulation technology such as EXACT, for patients with rare neurological diseases; its lead product candidates comprise NGN-401, an AAV9-based therapy in Phase 1/2 and advancing to the registrational Embolden trial for Rett syndrome in females ages 3 years and older, and NGN-101, a conventional gene therapy in Phase 1/2 for CLN5 Batten disease. The company maintains license agreements with The University of Edinburgh, Virovek Inc., Sigma-Aldrich Co. LLC, and Leland Stanford Junior University to support its pipeline development. Founded in 2018 and headquartered at 535 W 24th Street, 5th Floor, New York, New York, Neurogene operates primarily in the United States, with manufacturing capabilities in a 42,000 square foot facility in Houston, Texas, targeting pediatric and adult patients affected by devastating genetic neurological disorders. Recent developments include positive interim data from the pediatric cohort of the NGN-401 Phase 1/2 trial for Rett syndrome, demonstrating multidomain durable functional gains across all eight participants and continued skill acquisition; alignment with the U.S. Food and Drug Administration on the registrational Embolden trial design, including endpoint selection informed by key opinion leaders, caregivers, and payors, with expanded U.S. clinical trial sites and dosing initiation planned for late 2025; receipt of Regenerative Medicine Advanced Therapy designation for NGN-401; publication of preclinical data in Science Translational Medicine validating EXACT technology for regulated transgene expression in Rett syndrome models; a $200 million oversubscribed PIPE financing in November 2024 from investors including RTW Investments and Casdin Capital, extending cash runway into early 2028; and reallocation of capital to prioritize NGN-401 pivotal activities as of Q1 2025, with $292.6 million in cash equivalents and investments at March 31, 2025.
Company News
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Neurogene Inc. Announces Proposed Public Offering
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)